Pink Sheet

The Regulator and the Regulated Part I: A Conversation with FDA's Robert Temple and Amgen's Roger Perlmutter

01 Feb 2011

• By Ramsey Baghdadi

FDA’s dean of drug development Robert Temple and Amgen’s head of research and development Roger Perlmutter sat down for a conversation at the recent FDA/CMS Summit to discuss opportunities and challenges for biopharmaceutical developers in the current regulatory environment.

By Ramsey Baghdadi

Q: The RPM Report: How has FDA changed over the last five to ten years? Is it your view that...